经鼻蒸发式心脏骤停期间降温对院外心脏骤停后神经功能结局的影响:PRINCESS随机临床试验
PRINCESS国际多中心随机试验纳入677例旁观者目击的院外心脏骤停患者,比较经鼻蒸发式心脏骤停期间降温与入院后降温。主要结局90天良好神经功能结局(CPC 1-2)在干预组56/337(16.6%)vs 对照组45/334(13.5%),差异无统计学显著(RR 1.23,95%CI 0.86-1.72,P=0.25)。
要点
- 经鼻蒸发式心脏骤停期间降温未显著改善90天良好神经功能结局。
- 干预组达到核心体温<34°C中位时间105分钟 vs 对照组182分钟(P<0.001)。
- 干预组轻度鼻出血45/337(13%)为最常见设备相关不良事件,7天内不良事件率两组相似。
核心结论
- 在院外心脏骤停患者中,与常规护理相比,经鼻蒸发式心脏骤停期间降温未在90天良好神经功能结局方面产生统计学显著的改善。
研究设计与样本
- PRINCESS试验为研究者发起的随机国际多中心临床研究,采用盲法结局评估,由7个欧洲国家的急救医疗服务实施,时间为2010年7月至2018年1月,最终随访日期为2018年4月29日。
- 共纳入677例旁观者目击的院外心脏骤停患者,随机分配至经鼻蒸发式心脏骤停期间降温组(n=343)或标准护理组(n=334);两组入院后均接受32°C至34°C全身治疗性低温24小时。
主要发现
- 达到核心体温<34°C的中位时间:干预组105分钟 vs 对照组182分钟(P<0.001)。
- 90天CPC 1-2患者数:干预组56/337(16.6%)vs 对照组45/334(13.5%),差异3.1%(95%CI -2.3%至8.5%),RR 1.23(95%CI 0.86-1.72),P=0.25。
- 90天存活:干预组60/337(17.8%)vs 对照组52/334(15.6%),差异2.2%(95%CI -3.4%至7.9%),RR 1.14(95%CI 0.81-1.57),P=0.44。
- 轻度鼻出血为最常见设备相关不良事件,干预组45/337(13%)报告;7天内不良事件率两组相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Therapeutic hypothermia may increase survival with good neurologic outcome after cardiac arrest. Trans-nasal evaporative cooling is a method used to induce cooling, primarily of the brain, during cardiopulmonary resuscitation (ie, intra-arrest). OBJECTIVE: To determine whether prehospital trans-nasal evaporative intra-arrest cooling improves survival with good neurologic outcome compared with cooling initiated after hospital arrival. DESIGN, SETTING, AND PARTICIPANTS: The PRINCESS trial was an investigator-initiated, randomized, clinical, international multicenter study with blinded assessment of the outcome, performed by emergency medical services in 7 European countries from July 2010 to January 2018, with final follow-up on April 29, 2018. In total, 677 patients with bystander-witnessed out-of-hospital cardiac arrest were enrolled. INTERVENTIONS: Patients were randomly assigned to receive trans-nasal evaporative intra-arrest cooling (n = 343) or standard care (n = 334). Patients admitted to the hospital in both groups received systemic therapeutic hypothermia at 32°C to 34°C for 24 hours. MAIN OUTCOMES AND MEASURES: The primary outcome was survival with good neurologic outcome, defined as Cerebral Performance Category (CPC) 1-2, at 90 days. Secondary outcomes were survival at 90 days and time to reach core body temperature less than 34°C. RESULTS: Among the 677 randomized patients (median age, 65 years; 172 [25%] women), 671 completed the trial. Median time to core temperature less than 34°C was 105 minutes in the intervention group vs 182 minutes in the control group (P < .001). The number of patients with CPC 1-2 at 90 days was 56 of 337 (16.6%) in the intervention cooling group vs 45 of 334 (13.5%) in the control group (difference, 3.1% [95% CI, -2.3% to 8.5%]; relative risk [RR], 1.23 [95% CI, 0.86-1.72]; P = .25). In the intervention group, 60 of 337 patients (17.8%) were alive at 90 days vs 52 of 334 (15.6%) in the control group (difference, 2.2% [95% CI, -3.4% to 7.9%]; RR, 1.14 [95% CI, 0.81-1.57]; P = .44). Minor nosebleed was the most common device-related adverse event, reported in 45 of 337 patients (13%) in the intervention group. The adverse event rate within 7 days was similar between groups. CONCLUSIONS AND RELEVANCE: Among patients with out-of-hospital cardiac arrest, trans-nasal evaporative intra-arrest cooling compared with usual care did not result in a statistically significant improvement in survival with good neurologic outcome at 90 days. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01400373.
引用
- Nordberg P, Taccone FS, Truhlar A, et al. Effect of Trans-Nasal Evaporative Intra-arrest Cooling on Functional Neurologic Outcome in Out-of-Hospital Cardiac Arrest: The PRINCESS Randomized Clinical Trial. JAMA. 2019. PMID: 31063573. doi:10.1001/jama.2019.4149
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。